Aquinox Pharmaceuticals Announces Results From Phase 2 KINSHIP Trial With AQX-1125 in Patients With Atopic Dermatitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. HUVR:IN
2. ROIV
3. ANET
4. NKE
5. PANW
6. CL
7. SNDK
8. TAP
9. DELL
10. EAT

Go back to Aquinox Pharmaceuticals Announces Results From Phase 2 KINSHIP Trial With AQX-1125 in Patients With Atopic Dermatitis

Aquinox Pharma (AQXP) Reports Negative KINSHIP Trial Data; Cowen Maintains Outperform

November 3, 2015 2:22 PM EST

Cowen maintained an Outperform rating on Aquinox Pharmaceutical (NASDAQ: AQXP), and cut the price target to $23.00 (from $24.00), following negative KINSHIP trial data. The KINSHIP trial demonstrated AQX-1125 to be well tolerated and adverse events were consistent with prior clinical trials. No serious adverse... More

Needham & Company Keeps Aquinox Pharma (AQXP) at 'Buy'; Failure of AQX-1125 in Atopic Dermatitis Won't Impact Model

November 3, 2015 9:48 AM EST

Needham & Company affirms Aquinox Pharma (Nasdaq: AQXP) with a Buy rating and $25 price target after the company... More